Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer in China

References

• Thai AA, Solomon BJ, Sequist LV, Gainor JF, Heist RS. Lung cancer. Lancet. 2021;398(10299):535–554. doi:10.1016/S0140-6736(21)00312-3
   PubMed Web of Science ®Google Scholar
• Nasim F, Sabath BF, Eapen GA. Lung Cancer. Med Clin North Am. 2019;103(3):463–473. doi:10.1016/j.mcna.2018.12.006
   PubMed Web of Science ®Google Scholar
• Travis WD, Brambilla E, Burke A, Marx A, Nicholson AG. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. Lyon: International Agency for Research on Cancer; 2015.
   Google Scholar
• Wang M, Herbst RS, Boshoff C. Toward personalized treatment approaches for non-small-cell lung cancer. Nat Med. 2021;27(8):1345–1356. doi:10.1038/s41591-021-01450-2
   PubMed Web of Science ®Google Scholar
• Gou LY, Wu YL. Prevalence of driver mutations in non-small-cell lung cancers in the People’s Republic of China. Lung Cancer. 2014;5:1–9. doi:10.2147/LCTT.S40817
   PubMedGoogle Scholar
• Zhou F, Qiao M, Zhou C. The cutting-edge progress of immune-checkpoint blockade in lung cancer. Cell Mol Immunol. 2021;18(2):279–293. doi:10.1038/s41423-020-00577-5
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018;379(21):2040–2051. doi:10.1056/NEJMoa1810865
   PubMed Web of Science ®Google Scholar
• Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378(22):2078–2092. doi:10.1056/NEJMoa1801005
   PubMed Web of Science ®Google Scholar
• Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393(10183):1819–1830. doi:10.1016/S0140-6736(18)32409-7
   PubMed Web of Science ®Google Scholar
• Guidelines Working Committee of Chinese Society of Clinical Oncology. Guidelines of Chinese Society of Clinical Oncology (CSSO) Non-Small Cell Lung Cancer. Beijing: People’s medical publishing house; 2022.
   Google Scholar
• Wu B, Lu S. The effect of PD-L1 categories-directed pembrolizumab plus chemotherapy for newly diagnosed metastatic non-small-cell lung cancer: a cost-effectiveness analysis. Transl Lung Cancer Res. 2020;9(5):1770–1784. doi:10.21037/tlcr-19-605
   PubMed Web of Science ®Google Scholar
• Key to life. Available from: https://smzy.ilvzhou.com/. Accessed May 10, 2023.
   Google Scholar
• Liu G, Kang S, Wang X. Pharmacoeconomic evaluation of pembrolizumab in first- line treatment of advanced non- small cell lung cancer with high PD-L1 expression. China Pharm. 2021;32(11):1351–1356.
   Google Scholar
• Novello S, Kowalski DM, Luft A, et al. Pembrolizumab plus chemotherapy in squamous non-small-cell lung cancer: 5-year update of the phase III KEYNOTE-407 study. J Clin Oncol. 2023;41(11):1999–2006. doi:10.1200/JCO.22.01990
   PubMed Web of Science ®Google Scholar
• Measures for ethical review of life science and medical research involving humans; 2023. Available from: https://www.gov.cn/zhengce/zhengceku/2023-02/28/content_5743658.htm. Accessed June 22, 2023.
   Google Scholar
• Chinese Pharmaceutical Association. Chinese guidelines for pharmacoeconomic evaluations; 2020.
   Google Scholar
• Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics. 1998;13(4):397–409. doi:10.2165/00019053-199813040-00003
   PubMed Web of Science ®Google Scholar
• Cai D, Shi S, Jiang S, et al. Estimation of the cost-effective threshold of a quality-adjusted life year in China based on the value of statistical life. Eur J Health Econ. 2022;23(4):607–615. doi:10.1007/s10198-021-01384-z
   PubMed Web of Science ®Google Scholar
• National Bureau Of Statistics. National annual data; 2023. Available from: https://data.stats.gov.cn/easyquery.htm?cn=C01. Accessed March 12, 2023.
   Google Scholar
• Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316(10):1093–1103. doi:10.1001/jama.2016.12195
   PubMed Web of Science ®Google Scholar
• Shen Y, Wu B, Wang X, Zhu J. Health state utilities in patients with advanced non-small-cell lung cancer in China. J Comp Ef Res. 2018;7:443–452. doi:10.2217/cer-2017-0069
   PubMed Web of Science ®Google Scholar
• National Health Industry Data Platform. Bid winning information of drugs; 2023. Available from: https://www.yaozh.com/. Accessed May 15, 2023.
   Google Scholar
• Cheng R, Zhou Z, Liu Q. Cost-effectiveness of first-line versus second-line use of domestic anti-PD-1 antibody sintilimab in Chinese patients with advanced or metastatic squamous non-small cell lung cancer. Cancer Med. 2023;12(6):7389–7397. doi:10.1002/cam4.5440
   PubMed Web of Science ®Google Scholar
• Zhou D, Luo X, Zhou Z, et al. Cost-effectiveness analysis of tislelizumab, nivolumab and docetaxel as second- and third-line for advanced or metastatic non-small cell lung cancer in China. Front Pharmacol. 2022;13:880280. doi:10.3389/fphar.2022.880280
   PubMed Web of Science ®Google Scholar
• Luo X, Zhou Z, Zeng X, Liu Q. The cost-effectiveness of tislelizumab plus chemotherapy for locally advanced or metastatic nonsquamous non-small cell lung cancer. Front Pharmacol. 2022;13:935581. doi:10.3389/fphar.2022.935581
   PubMed Web of Science ®Google Scholar
• Lazzari C, Spagnolo CC, Ciappina G, et al. Immunotherapy in early-stage Non-Small Cell Lung Cancer (NSCLC): current evidence and perspectives. Curr Oncol. 2023;30(4):3684–3696. doi:10.3390/curroncol30040280
   PubMed Web of Science ®Google Scholar
• Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–1833. doi:10.1056/NEJMoa1606774
   PubMed Web of Science ®Google Scholar
• Carbone DP, Reck M, Paz-Ares L, et al. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N Engl J Med. 2017;376(25):2415–2426. doi:10.1056/NEJMoa1613493
   PubMed Web of Science ®Google Scholar
• Govindan R, Szczesna A, Ahn MJ, et al. Phase III trial of ipilimumab combined with paclitaxel and carboplatin in advanced squamous non-small-cell lung cancer. J Clin Oncol. 2017;35(30):3449–3457. doi:10.1200/JCO.2016.71.7629
   PubMed Web of Science ®Google Scholar
• Insinga RP, Vanness DJ, Feliciano JL, et al. Cost-effectiveness of pembrolizumab in combination with chemotherapy versus chemotherapy and pembrolizumab monotherapy in the first-line treatment of squamous non-small-cell lung cancer in the US. Curr Med Res Opin. 2019;35(7):1241–1256. doi:10.1080/03007995.2019.1571297
   PubMed Web of Science ®Google Scholar
• Zhang YJ, Ren Y, Zheng Q, et al. The impact of national centralized drug procurement on health expenditures for lung cancer inpatients: a difference-in-differences analysis in a large tertiary hospital in China. Front Public Health. 2022;10:956823. doi:10.3389/fpubh.2022.956823
   PubMed Web of Science ®Google Scholar